HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Chia-Chi Lin Selected Research

sabatolimab

1/2021Phase I/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Chia-Chi Lin Research Topics

Disease

69Neoplasms (Cancer)
10/2022 - 09/2004
41Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
02/2022 - 05/2008
13Esophageal Squamous Cell Carcinoma
10/2022 - 07/2007
13Carcinoma (Carcinomatosis)
01/2020 - 09/2004
12Neoplasm Metastasis (Metastasis)
06/2022 - 03/2007
12Disease Progression
02/2022 - 06/2016
8Esophageal Neoplasms (Esophageal Cancer)
07/2022 - 11/2002
7Hepatocellular Carcinoma (Hepatoma)
06/2022 - 02/2007
7Adenocarcinoma
01/2020 - 11/2015
7Lung Neoplasms (Lung Cancer)
01/2020 - 09/2014
5Prostatic Neoplasms (Prostate Cancer)
01/2022 - 03/2006
5Diarrhea
09/2021 - 03/2013
5Fatigue
09/2021 - 10/2016
5Thyroid Neoplasms (Thyroid Cancer)
01/2021 - 01/2017
4Squamous Cell Carcinoma of Head and Neck
02/2022 - 11/2016
3Nausea
01/2022 - 03/2013
3Thymoma (Thymic Carcinoma)
01/2022 - 01/2018
3Breast Neoplasms (Breast Cancer)
10/2021 - 01/2007
3Exanthema (Rash)
09/2021 - 05/2009
3Hypertension (High Blood Pressure)
01/2021 - 05/2009
3Hemorrhage
01/2021 - 04/2018
3Urinary Bladder Neoplasms (Bladder Cancer)
11/2019 - 10/2009
3Infections
12/2017 - 06/2002
3Squamous Cell Carcinoma (Epidermoid Carcinoma)
09/2017 - 11/2015
2Anaplastic Thyroid Carcinoma
06/2022 - 10/2020
2Melanoma (Melanoma, Malignant)
01/2021 - 01/2020
2Colorectal Neoplasms (Colorectal Cancer)
01/2021 - 02/2020
2Febrile Neutropenia
12/2020 - 08/2011
2Adenocarcinoma of Lung
01/2020 - 01/2020
2Lymphoma (Lymphomas)
01/2019 - 08/2015
2Thrombocytopenia (Thrombopenia)
01/2019 - 08/2011
2Stomach Neoplasms (Stomach Cancer)
09/2017 - 06/2016
2Renal Cell Carcinoma (Grawitz Tumor)
06/2014 - 03/2013
2Carcinogenesis
07/2008 - 01/2006

Drug/Important Bio-Agent (IBA)

24ErbB Receptors (EGF Receptor)IBA
01/2020 - 03/2006
22Cisplatin (Platino)FDA LinkGeneric
07/2022 - 11/2002
20Tyrosine Kinase InhibitorsIBA
01/2020 - 01/2009
12Paclitaxel (Taxol)FDA LinkGeneric
07/2022 - 03/2006
12Gefitinib (Iressa)FDA Link
01/2017 - 03/2006
11Fluorouracil (Carac)FDA LinkGeneric
06/2019 - 11/2002
8Leucovorin (Folinic Acid)FDA Link
06/2019 - 11/2002
8Erlotinib Hydrochloride (CP 358,774)FDA Link
01/2017 - 05/2009
7B7-H1 AntigenIBA
07/2022 - 11/2016
7pembrolizumabIBA
06/2022 - 06/2016
6Biomarkers (Surrogate Marker)IBA
10/2022 - 09/2010
6Anaplastic Lymphoma KinaseIBA
01/2022 - 09/2015
5PlatinumIBA
01/2022 - 10/2011
5lorlatinibIBA
01/2022 - 12/2018
5Pharmaceutical PreparationsIBA
09/2021 - 11/2017
5AfatinibIBA
01/2017 - 03/2016
4spartalizumabIBA
06/2022 - 01/2020
4LigandsIBA
02/2022 - 11/2019
4DNA (Deoxyribonucleic Acid)IBA
01/2021 - 01/2013
4osimertinibIBA
01/2021 - 01/2017
4GemcitabineFDA Link
08/2018 - 04/2007
3Alkaline PhosphataseIBA
01/2022 - 03/2007
3Immune Checkpoint InhibitorsIBA
12/2021 - 10/2019
3Phosphotransferases (Kinase)IBA
10/2021 - 04/2014
3Proteins (Proteins, Gene)FDA Link
05/2021 - 11/2019
3Monoclonal AntibodiesIBA
05/2021 - 09/2017
3Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)IBA
01/2021 - 06/2014
3Aspartate Aminotransferases (Aspartate Transaminase)IBA
01/2021 - 11/2017
3cabozantinibIBA
01/2021 - 02/2013
3RamucirumabIBA
01/2021 - 01/2020
3CrizotinibIBA
01/2020 - 12/2018
3Arsenic Trioxide (Trisenox)FDA Link
11/2008 - 09/2004
3Methotrexate (Mexate)FDA LinkGeneric
01/2007 - 11/2002
2sapanisertibIBA
05/2022 - 01/2022
2siremadlinIBA
03/2022 - 01/2022
2AntibodiesIBA
01/2022 - 05/2021
2LY3300054IBA
12/2021 - 01/2021
2trastuzumab deruxtecanIBA
11/2021 - 10/2021
2entrectinibIBA
10/2021 - 01/2020
2pexidartinibIBA
01/2021 - 01/2020
2Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA
01/2021 - 06/2014
2Creatine Kinase (Creatine Phosphokinase)IBA
01/2021 - 10/2016
2Alanine Transaminase (SGPT)IBA
01/2020 - 11/2017
2Epidermal Growth Factor (EGF)IBA
11/2019 - 09/2010
2NivolumabIBA
01/2018 - 01/2018
2Sorafenib (BAY 43-9006)FDA Link
01/2017 - 08/2011
2Dihydrotachysterol (AT 10)IBA
11/2016 - 05/2009
2Pemetrexed (MTA)FDA Link
03/2016 - 09/2014
24- amino- 5- fluoro- 3- (5- (4- methylpiperazin- 1- yl)- 1H- benzimidazol- 2- yl)quinolin- 2(1H)- oneIBA
06/2014 - 03/2013
2Fibroblast Growth Factors (Fibroblast Growth Factor)IBA
06/2014 - 03/2013
2Drug CombinationsIBA
09/2013 - 07/2007
2Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
03/2013 - 05/2009
2Bevacizumab (Avastin)FDA Link
01/2013 - 05/2009
2Oxidoreductases (Dehydrogenase)IBA
08/2011 - 01/2009

Therapy/Procedure

32Therapeutics
10/2022 - 04/2007
26Drug Therapy (Chemotherapy)
01/2022 - 11/2002
7Chemoradiotherapy
08/2019 - 10/2009
6Esophagectomy
08/2019 - 06/2009
5Neoadjuvant Therapy
07/2022 - 06/2009
4Induction Chemotherapy
11/2019 - 10/2009
4Radiotherapy
08/2018 - 06/2009
3Immunotherapy
06/2022 - 01/2018
3Castration
01/2022 - 02/2013
3Combination Drug Therapy (Combination Chemotherapy)
01/2014 - 11/2002
2Duration of Therapy
02/2022 - 11/2017
2TP protocol
06/2019 - 01/2007